Alzheimer’s drug approval controversy

By arguing the A→T→N model is robust and acknowledging modest clinical effects of anti-amyloid drugs like Aduhelm, the piece underpins decisions about approving and reimbursing costly anti-amyloid therapies, shaping evidence thresholds and Medicare policy.

Article claims approved anti-amyloid antibodies cost tens of thousands annually yet offer imperceptible benefit and notable risks.